Status
Conditions
Treatments
About
To investigate gene expression profile and immunological associated analysis relating to immunotherapy response of patients with malignant tumor presenting malignant cavity effusion after DC-CIK immunotherapy.
Full description
The patients with malignant cavity effusion are treated with dendritic cells (DC) plus cytokine induced killer cells (CIK) locally. Malignant cavity effusion from cancer patients is obtained through puncture and is centrifugalized to get supernatant fluid and enrich cancer cells before and after the therapy. The enriched cancer cells which are flash frozen, as well as the supernatant, are stored at -80°C until processing. The T-Cell Receptor/B-Cell Receptor gene expression in cavity effusion is detected by micro-array to explore the mechanism that DC-CIK immunotherapy controls the malignant cavity effusion. Statistical analysis is performed using unsupervised hierarchical cluster.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
30 participants in 1 patient group
Loading...
Central trial contact
Jun Ren, MD, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal